Comparative rates of adverse events with different formulations of intravenous iron

被引：42

作者：

Okam, Maureen M. ^{[1
]}

Mandell, Elyse ^{[1
]}

Hevelone, Nathanael ^{[3
]}

Wentz, Rachel ^{[1
]}

Ross, Ainsley ^{[1
]}

Abel, Gregory A. ^{[2
,4
]}

机构：

[1] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Dept Med Oncol, Div Populat Sci, Boston, MA 02115 USA

[3] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA

[4] Dana Farber Canc Inst, Dept Med Oncol, Ctr Leukemia, Boston, MA 02115 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2012年 / 87卷 / 11期

关键词：

CHEMOTHERAPY-RELATED ANEMIA; EVERY; 3; WEEKS; ORAL IRON; CONTROLLED-TRIAL; DEXTRAN; EFFICACY; SAFETY; INFUSION; ALPHA; SUPPLEMENTATION;

D O I：

10.1002/ajh.23322

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E123 / E124

页数：2

共 26 条

[1] Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial [J].

Auerbach, M ;

Ballard, H ;

Trout, JR ;

McIlwain, M ;

Ackerman, A ;

Bahrain, H ;

Balan, S ;

Barker, L ;

Rana, J .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1301-1307

[2] Intravenous iron: From anathema to standard of care [J].

Auerbach, Michael ;

Coyne, Dan ;

Ballard, Harold .

AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (07) :580-588

[3] Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia [J].

Auerbach, Michael ;

Pappadakis, Jennifer A. ;

Bahrain, Huzefa ;

Auerbach, Sarah A. ;

Ballard, Harold ;

Dahl, Naomi V. .

AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (10) :860-862

[4] Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety [J].

Auerbach, Michael ;

Ballard, Harold .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2010, :338-347

[5] Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia [J].

Auerbach, Michael ;

Silberstein, Peter T. ;

Webb, R. Timothy ;

Averyanova, Svetlana ;

Ciuleanu, Tudor-Eliade ;

Shao, James ;

Bridges, Kenneth .

AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (09) :655-663

[6] Comparison of rates of reported adverse events associated with i.v. iron products in the United States [J].

Bailie, George R. .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (04) :310-320

[7] Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation [J].

Barton, JC ;

Barton, EH ;

Bertoli, LF ;

Gothard, CH ;

Sherrer, JS .

AMERICAN JOURNAL OF MEDICINE, 2000, 109 (01) :27-32

[8] Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia [J].

Bastit, Laurent ;

Vandebroek, An ;

Altintas, Sevilay ;

Gaede, Bernd ;

Pinter, Tamas ;

Suto, Tamas S. ;

Mossman, Tony W. ;

Smith, Kay E. ;

Vansteenkiste, Johan F. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1611-1618

[9] Iron Status and Analysis of Efficacy and Safety of Ferric Carboxymaltose Treatment in Patients with Inflammatory Bowel Disease [J].

Beigel, Florian ;

Loehr, Beate ;

Laubender, Ruediger P. ;

Tillack, Cornelia ;

Schnitzler, Fabian ;

Breiteneicher, Simone ;

Weidinger, Maria ;

Goeke, Burkhard ;

Seiderer, Julia ;

Ochsenkuehn, Thomas ;

Brand, Stephan .

DIGESTION, 2012, 85 (01) :47-54

[10] Update on adverse drug events associated with parenteral iron [J].

Chertow, GM ;

Mason, PD ;

Vaage-Nilsen, O ;

Ahlmén, J .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (02) :378-382

← 1 2 3 →